Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
Molecular basis for melatonin's oncostatic effects determined
August 11th, 2005
The molecular basis for melatonin's oncostatic effects on breast tumor cells has been identified and characterized. "Melatonin is endowed with a growth inhibitory effect in MCF-7 breast cancer cells whose mechanism has been related to an antiestrogenic activity exerted by inhibition of binding of the estradiol-estrogen receptor complex to its DNA responsive element," researchers in Italy explained. "Looking for downstream gene determinants of this effect," G. Cini and colleagues at the University of Florence "performed a transcriptome profiling by high-density microarrays of estrogen-treated MCF-7 cells exposed or not to melatonin." ...
Source: Women's Health Weekly (2005-08-11)
|
